ARCHIVES

Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says.

This article is from The Cancer Letter archive.

Vol. 30 No. 19 | May 7, 2004

Download PDF Visit The Full Archive

Related Articles

FDA Approves Afinitor Tablets For Advanced Breast Cancer

August 31, 2012

New CREG Cell Kinetics Study Axed By DCTBSC

March 31, 1978

FY 2000 Budget: Success Rate Drops Projected, Would Take Years to Catch Up

February 19, 1999

Major Emphasis Switch; Outreach Core Support Ends In Favor Of Cancer Control Research

January 22, 1982

Sharp Increase In Cancer Mortality Could Bring Drastic Program Changes; All 1975 Data Needed

December 12, 1975

CHOP Evaluation Plan In Jan. 22 Issue

January 15, 1982